compounded tirzepatide
Selected indexed studies
- Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program. (Obesity (Silver Spring), 2023) [PMID:36478180]
- Compounded Tirzepatide Therapy for Weight Loss: A Health Economics & Outcomes Research (HEOR) Analysis. (Int J Pharm Compd, 2025) [PMID:39921911]
- Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown. (Ann Pharmacother, 2026) [PMID:41689811]
_Worker-drafted node — pending editorial review._
Connections
compounded tirzepatide is a side effect of
Sources
- Documentation of Compounded GLP-1 Receptor Agonists in a Large Primary Care Dataset. (2025) pubmed
- Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system. (2026) pubmed
- Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado. (2025) pubmed
- Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown. (2026) pubmed
- Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical Practice. (2025) pubmed
- Global Rise of Compounded Weight-Loss Medicines: A Worrisome Trend. (2025) pubmed
- Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program. (2023) pubmed
- Compounded Tirzepatide Therapy for Weight Loss: A Health Economics & Outcomes Research (HEOR) Analysis. (2025) pubmed
- A novel, widespread impurity in mass-compounded tirzepatide/B12 products: potential patient safety implications. (2026) pubmed
- Compounded incretins in clinical practice: An opinion of the endocrine and metabolism practice and research network of the American College of Clinical Pharmacy. (2025) pubmed